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Abstract
Background: Little is known about the induction of humoral responses directed against human autoantigens
during acute inflammation. We utilized a highly sensitive antibody profiling technology to study autoantibodies in
patients with acute respiratory distress syndrome (ARDS) and severe sepsis, conditions characterized by intensive
immune activation leading to multiple organ dysfunction.
Methods: Using Luciferase Immunoprecipitation Systems (LIPS), a cohort of control, ARDS and sepsis patients were
tested for antibodies to a panel of autoantigens. Autoantibody titers greater than the mean plus 3 SD of the 24
control samples were used to identify seropositive samples. Available longitudinal samples from different
seropositive ARDS and sepsis patient samples, starting from within the first two days after admission to the
intensive care, were then analyzed for changes in autoantibody over time.
Results: From screening patient plasma, 57% of ARDS and 46% of septic patients without ARDS demonstrated at
least one statistically significant elevated autoantibody compared to the controls. Frequent high titer antibodies
were detected against a spectrum of autoantigens including potassium channel regulator, gastric ATPase, glutamic
decarboxylase-65 and several cytokines. Analysis of serial samples revealed that several seropositive patients had
low autoantibodies at early time points that often rose precipitously and peaked between days 7-14. Further, the
use of therapeutic doses of corticosteroids did not diminish the rise in autoantibody titers. In some cases, the
patient autoantibody titers remained elevated through the last serum sample collected.
Conclusion: The rapid induction of autoantibodies in ARDS and severe sepsis suggests that ongoing systemic
inflammation and associated tissue destruction mediate the break in tolerance against these self proteins.
Introduction
Serum antibodies are essential components of adaptive
immunity, but are also involved in the pathogenesis of
many autoimmune diseases. While much is known about
the control of host antibody production following patho-
gen exposure or vaccination [1], the induction of autoan-
tibodies in human autoimmune and other diseases
remains poorly defined. In genetically susceptible indivi-
duals, infection and other environmental insults have
been speculated to trigger immune responses by different
mechanisms including induction of cytokines, stimula-
tion of toll-like receptors and other pattern recognition
receptors, the release of self antigens by damaged cells
and tissues and/or molecular mimicry [2]. However to
date, little is known about the spectrum of autoantibody
responses and the kinetics of autoantibody induction
during acute infection and systemic inflammation.
Acute respiratory distress syndrome (ARDS) and severe
sepsis are acute inflammatory conditions associated with
high morbidity and mortality, often involving multiple
organ failure [3,4]. ARDS is caused by a wide variety of
infectious or inflammatory insults to the lung that may
occur by direct (e.g. pneumonia) or indirect injury (e.g.
peritonitis). The pathologic hallmarks of ARDS are dif-
fuse alveolar damage manifested by disruption of the
alveolar-capillary interface, as well as the accumulation of
inflammatory cells and protein-rich exudates in the
alveolar spaces [4]. Patients with ARDS have elevated
levels of inflammatory mediators such as TNF-a,I L - 1 b,
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any medium, provided the original work is properly cited.IL-6 and IL-8 in lung lining fluid as well as in the circula-
tion [5]. In sepsis a nidus of infection causes a local and
systemic inflammatory response [3]. However as sepsis
persists, there is a rapid shift towards an anti-inflamma-
tory immunosuppressive state that likely involves T-cell
anergy [6,7], increased anti-inflammatory cytokines [8]
and the loss of dendritic cells, B lymphocytes and CD4+
T lymphocytes [9,10].
Luciferase immunoprecipitation systems (LIPS), offers
ah i g h l yq u a n t i t a t i v ea n ds e n s i t i v em e t h o dt om e a s u r e
antibody responses against large numbers of foreign
antigens and autoantigens [11-16]. In this study, LIPS
was used to profile plasma from patients with ARDS or
sepsis against a panel of known autoantigens. Within 10
to 14 days after the onset of illness, nearly 50% of the
patients show high antibody titers to at least one auto-
antigen. Remarkably, analysis of serial samples revealed
that the induction of these autoantibodies occurred
rapidly, often within 1-7 days after intensive care unit
admission and in some cases remained elevated for sev-
eral weeks. The mechanisms and time course for the
rapid induction of autoantibodies seen in ARDS and
sepsis may occur in other conditions including autoim-
mune diseases.
Methods
Patient Samples
Plasma samples were obtained from patients and healthy
control subjects under institutional review board-
approved protocols at the NIH Clinical Center and from
the University of Tennessee Health Science Center [17].
Plasma samples were obtained from heparinized venous
whole blood by centrifugation and stored in aliquots at
-80°C. Plasma samples from the 24 normal volunteers
were collected at the NIH Clinical Center, while the 35
ARDS patients were selected from a randomized trial
investigating prolonged methylprednisolone treatment in
early severe ARDS conducted at the University of Ten-
nessee [17]. The 13 patients with sepsis were selected
from a randomized trial investigating prolonged hydro-
cortisone therapy in severe sepsis not complicated by
ARDS, also conducted at the University of Tennessee
Health Science Center. These ARDS and sepsis plasma
samples were used in this retrospective, exploratory
study to examine whether autoantibodies are generated
in periods of acute inflammation. Samples were selected
from patients whom time points were available at least 7
days into acute inflammatory conditions. We attempted
to use samples from patients with positive culture results:
all patients in the sepsis cohort had positive culture
results, as did 80% of the patients in the ARDS cohort.
As part of a clinical protocol, all ARDS and sepsis
patients were in the intensive care unit (ICU) and evalu-
ated with a battery of clinical tests including lung injury
scores (LIS) and multiple organ dysfunction syndrome
(MODS) scores. For the 35 ARDS patients, 22 patients
were treated with methylprednisolone and 13 were not
treated with steroids. For severe sepsis patients, ten
received stress-doses of hydrocortisone, and three did
not. The characteristics of the ARDS and sepsis patients
are summarized in Table 1 and include age, gender,
APACHE 3 scoring, methylprednisolone/hydrocortisone
treatment frequency, infection status and in-hospital sur-
vival rate. None of the patients had a known history of
autoimmune disorders or were receiving outpatient treat-
ment with corticosteroids or other immunosuppressants
prior to clinical presentation.
Ruc-antigen fusions and LIPS analysis
Many of the autoantigens used in these LIPS studies
including those for glutamic decarboxylase-65 (GAD65),
A Q P - 4 ,g a s t r i cA T P a s ea n daf r a g m e n to fR o 5 2( R o 5 2 -
Δ2) have been previously described [14-16]. Four cyto-
kines (Interferon-g, Interferon-ω, Interleukin-6 and
interleukin-1a) corresponding to the processed cytokine
missing the signal peptide sequences were also gener-
ated as C-terminal Ruc-antigen fusions [18]. In addition
a new lung autoantigen, KCNRG and four other cyto-
kines were constructed as C-terminal antigen fusions
downstream of Renilla luciferase (Ruc) using the pREN2
vector [13]. DNA sequencing was used to ensure the
integrity of this new construct.
LIPS assay was performed at room temperature as
described [19]. In these assays, sera were processed in a
96-well format. A “master plate” was first constructed
by diluting patient sera 1:10 in assay buffer A (50 mM
T r i s ,p H7 . 5 ,1 0 0m MN a C l ,5m MM g C l 2,1 %T r i t o n
X-100) in a 96-well polypropylene microtiter plate. For
evaluating antibody titers by LIPS, 40 μl of buffer A,
10 μl of diluted human sera (1 μl equivalent), and 1 ×
10
7 light units (LU) of Ruc-antigen Cos1 cell extract,
diluted in buffer A to a volume of 50 μl, were added to
each well of a polypropylene plate and incubated for
60 minutes at room temperature on a rotary shaker.
Next, 5 μl of a 30% suspension of Ultralink protein A/G
beads (Pierce Biotechnology, Rockford, IL) in PBS were
added to the bottom of each well of a 96-well filter HTS
plate (Millipore, Bedford, MA). To this filter plate, the
100 μl antigen-antibody reaction mixture was trans-
ferred and incubated for 60 minutes at room tempera-
ture on a rotary shaker. The washing steps of the
retained protein A/G beads were performed on a Tecan
plate washer with a vacuum manifold. After the final
wash, LU were measured in a Berthold LB 960 Centro
microplate luminometer (Berthold Technologies, Bad
Wilbad, Germany) using coelenterazine substrate mix
(Promega, Madison, WI). All light unit (LU) data were
obtained from the average of two separate experiments
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A/G bead binding. Patient samples positive at day 10 for
ARDS or day 14 for sepsis were reexamined for changes
in antibody titers using all available serial samples.
Statistical analysis
GraphPad Prism software (San Diego, CA) was used for
statistical analysis. Due to the overdispersed nature of
the autoantibody titers, the healthy control subjects
(CTRL) are reported as the geometric mean titer (GMT)
± 95% confidence interval. For determining the cut-off
limits for each of the LIPS tests, the mean value of the
24 control samples plus 3 standard deviations (SD) in
the first cohort was used and is indicated in the figures.
The non-parametric Mann-Whitney U test was used for
comparison of antibody titers in different groups. Using
contingency tables, the Fischer’s exact test was used to
determine the statistical significance between autoanti-
body seropositivity and in-hospital survival.
Data transformation and a heatmap were used to visua-
lize the autoantibody profiles of the participants as a sin-
gle graphic. In order to create this heatmap, the mean
and standard deviation of the antibody titers for each
antigen in the 24 control samples was first generated as a
reference scale. Next, antibody titer values for each anti-
gen-antibody measurement greater than the control
mean plus 3 SD were color-coded to signify the relative
number of standard deviations above these cut-off values.
Lastly, the samples were rank ordered with respect to
anti-KCNRG autoantibodies, the most informative auto-
antigen in the ARDS and sepsis patients.
Results
Detection of high titer autoantibodies to proinflammatory
cytokines in selected ARDS and sepsis patients
Based on the hypothesis that anti-cytokine autoantibodies
might predispose a patient to infection or inflammation,
24 controls, 35 ARDS and 13 sepsis patients were screened
for autoantibodies to a panel of cytokines using LIPS. To
increase the likelihood of detecting anti-cytokine antibo-
dies at peak levels, patient samples were analyzed from
ARDS at day 14 and sepsis at day 10. Since the normal
range of anti-cytokine autoantibody titers is not known,
and in order to facilitate the identification of elevated anti-
cytokine autoantibodies, a cut-off threshold based on auto-
antibody titers greater than the mean plus 3 SD of the 24
control samples was used to identify potential seropositive
samples. Based on this criterion, a selected number of
ARDS and sepsis patients showed autoantibodies against
several cytokines that were often 10 to 1,000-fold higher
than the GMT of the controls (Figure 1). For example,
three ARDS serum samples had high anti-interleukin-6
Table 1 Clinical Characteristics Based on Autoantibody Status
Autoantibody Positive
a (n = 20) Autoantibody Negative
a (n = 15)
ARDS
Age yrs (mean ± SD) 45 ± 14 52 ± 16
Gender 8 male (40%) 10 male (67%)
APACHE 3 score (mean ± SD) 58 ± 17 62 ± 16
Methylprednisolone treatment
b 13/20 (65%) 9/15 (60%)
Infections Gram positive bacteria: 12
Gram negative bacteria: 3
Fungal: 1
Culture negative: 5
Gram positive bacteria: 4
Gram negative Bacteria: 7
Fungal: 1
Viral: 1
Culture negative: 2
In-hospital survival 18/20 (90%) 9/15 (60%)
Severe Sepsis
Autoantibody Positive
a (n = 6) Autoantibody Negative
a (n = 7)
Age yrs (mean ± SD) 54 ± 21 63 ± 18
Gender 5 male (83%) 7 male (100%)
APACHE 3 score (mean ± SD) 75 ± 26 68 ± 23
Hydrocortisone treatment
c 5/6 (83%) 5/7 (71%)
Infections Gram positive bacteria: 6
Gram negative bacteria: 0
Gram positive bacteria: 3
Gram negative bacteria: 4
In-hospital survival 4/6 (67%) 5/7 (71%)
aAs determined by LIPS.
bMethylprednisolone dose - 1 mg/kg/day for 14 days then tapered.
cHydrocortisone dosage - 300 mg initially then 10 mg per hour for seven days.
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and 255,074 LU, which were all markedly higher than the
GMT of anti-IL-6 antibodies in the controls with a value
of 2,347 LU [95% confidence interval (CI); 2,080-2,649]
(Figure 1A). As shown in Figure 1B, two ARDS samples
were positive for anti-interferon-ω (INF-ω) autoantibodies
with values of 34,348 and 70,779 LU, while the GMT of
the control group was only 8,658 LU (95% CI; 7,993-
9,379). Significantly elevated anti-interferon-g (INF-g) anti-
bodies were also detected in one ARDS and one septic
patient (Figure 1C). Finally, one ARDS sample showed a
positive anti-interleukin-1a (IL1-a) antibody titer of
1,136,872 LU, which was above the cut-off derived from
the controls (Figure 1D). Testing a number of other cyto-
kines, including interferon-a, BAFF (TNF family member),
April (a proliferation-inducing ligand) and IL-12, did not
reveal autoantibody positivity in any of the ARDS or sepsis
patients (data not shown). Together these results suggest
that some ARDS and sepsis patients generate high levels
of serum autoantibodies to certain cytokines which might
reflect autoimmunization against these particular cyto-
kines seen in these patients.
Detection of immunoreactivity to diverse autoantigen
targets in ARDS and sepsis
In light of detecting anti-cytokine autoantibodies in both
ARDS and sepsis patients, other potential autoantigens
were also evaluated. Since we hypothesized that ARDS
and septic patients might show immunoreactivity with
antigens derived from damaged tissue and organs, we
tested a panel of known autoantigens associated with
several autoimmune diseases. The autoantigens Jo-1,
MuSK, and La failed to show any statistically significant
responses in both patients with ARDS and those with
severe sepsis (data not shown). From screening several
other autoantigens, we detected autoantibodies against
the lung-specific autoantigen potassium channel regula-
tor (KCNRG). Although the anti-KCNRG autoantibody
titers were modestly elevated compared to the anti-cyto-
kine autoantibodies, 23% (8/35) of the ARDS and 25%
(3/12) of the sepsis patients had statistically significant
autoantibody titers that were higher than the control
cut-off (Figure 1E). Mann Whitney U test analysis
revealed significantly higher detectable anti-KCNRG
autoantibody titers in both the ARDS (P <0 . 0 0 6 )a n d
sepsis patient groups (P < 0.03) compared to the con-
trols (Figure 1E). These results suggest that the KCNRG
protein is a target of autoantibodies in patients with
ARDS and sepsis.
Screening of several other autoantigens, including gas-
tric ATPase, GAD65, AQP-4 and Ro52 also revealed
high titer autoantibodies in several patients from the
ARDS and severe sepsis cohorts. For example, elevated
anti-gastric ATPase autoantibodies, higher than the cut-
off derived from the controls, were found in 14% of the
ARDS patients (5/35) as well as one patient with severe
Figure 1 Autoantibodies in patients with ARDS or severe sepsis. Shown are results from 24 controls, 35 ARDS and 13 sepsis patients. Each
symbol represents a sample from one individual patient. The autoantibody titers for (A) IL-6 (B) IFN-ω, (C) IFN-g, (D) IL1-a, (E) KCNRG and (F)
gastric ATPase, (G) AQP-4 and (H) Ro52 antibody titers are plotted on the Y-axis using a log10 scale. The geometric mean antibody titer for the
ARDS, sepsis and controls are shown by the short solid lines. The dashed line represents the cut-off level for determining seropositivity and is
derived from the mean plus 3 SD of the antibody titer of the 24 controls. P values were calculated using the Mann Whitney U test and were
only significant for anti-KCNRG autoantibodies (control vs. ARDS; P = 0.006 and control vs. sepsis; P = 0.03).
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revealed that 9% (3/35) of the ARDS and 15% (2/13) of
sepsis samples had antibody titers above the cut-off
value of the mean plus 3 SD of the 24 control samples
(Figure 1G). High titer autoantibodies above the control
cut-off were also detected to GAD65 in three ARDS and
two sepsis patients (data not shown). Lastly, one ARDS
and one sepsis patient had statistically significant levels
of autoantibodies to Ro52 (Figure 1H). Together, these
results suggest that ARDS and sepsis patients have a
high frequency of autoantibodies against a number of
diverse autoantigen targets that are classically associated
with several different autoimmune conditions.
Autoantibody profiles in ARDS and sepsis
To more easily understand patient immunoreactivity to
the different antigens and relative titers, a colored heat-
map was employed. For this heatmap, antibody titer
values for each antigen-antibody measurement greater
than the cut-off of the control mean plus 3 SD were
color-coded to signify the relative number of standard
deviations above these cut-off values. Analysis of con-
trols revealed that 5 of the normal volunteers showed
positive single autoantibody responses in the range of
3 - 4S D( d a t an o ts h o w na n dF i g u r e1 ) .I nc o n t r a s t ,
some but not all ARDS and sepsis patients showed het-
erogeneous immunoreactivity to the autoantigen panel
with antibody titers ranging from 3 to 394 SD above the
mean of controls (Figure 2). The most frequently posi-
tive autoantigen was the KCNRG lung protein, followed
by the gastric ATPase, AQP-4, GAD65 neural autoanti-
gens and finally the Ro52 protein (Figure 2). As evident
from the heatmap, several of the ARDS and septic
shock patients showed positive autoantibody responses
to multiple autoantigens. In general, patients showing
autoantibodies to multiple targets were patients with the
highest autoantibody titers. The most dramatic example
of this was a patient with bacterial meningitis (S3) who
showed high titer autoantibodies to four different auto-
antigens including KCNRG, AQP-4, GAD65 and INF-g
(Figure 2). Some of the other patients with high titer
anti-cytokine autoantibodies also showed interesting
co-profiles: two ARDS patients (A14 and A30) were
co-positive for only IL-6 and interferon-ω autoantibo-
dies, one ARDS patient (A35) was co-positive for IL-1a
and ATPase autoantibodies and one sepsis patient (S13)
with interferon-g autoantibodies was also positive for
anti-KCNRG and anti-GAD65 autoantibodies (Figure 2).
Inspection of the heatmap also shows that there was no
difference in the prevalence or relative autoantibody in
patients treated with and without steroids (Figure 2 and
Table 1). Taken together these results highlight the het-
erogeneity of targets and autoantibody titers seen
acutely in ARDS and sepsis patients and suggest that
steroid treatment has little or no effect on the produc-
tion of autoantibodies in these conditions.
Since only 57% of ARDS and 46% of septic patients
demonstrated at least one statistically significant ele-
vated autoantibody compared to the controls, at present
it is difficult to make any general conclusions about the
predictive value of these autoantibodies for determining
severity. However, the relationship between short-term
survival and autoantibodies was examined. As shown in
Table 1, the ARDS autoantibody positive patients
showed a 90% (18/20) in-hospital survival rate, while the
autoantibody negative samples showed a 60% survival
rate (9/15). Similarly, the autoantibody positive sepsis
patients showed a 67% (4/6) survival rate and the auto-
antibody negative sepsis patients had a 71% (5/7) survi-
val rate. Statistical analysis using Fischer’s exact tests did
not reveal any significant differences between the differ-
ent groups. Lastly, this study with short-term samples
from ARDS and sepsis patients was not designed to ana-
lyze the significance of these autoantibodies as they
relate to long-term morbidity and mortality.
Kinetics of autoantibody induction in ARDS and sepsis
Since 57% of the ARDS and 46% of the septic shock
patients showed high antibody titers against at least one
autoantigen, we analyzed serial samples to determine
whether these were pre-existing antibodies or were gen-
erated during the acute inflammatory process. Available
longitudinal samples, typically 3-5 different samples
starting within the first two days after admission to the
ICU were analyzed. Analysis of the ARDS autoantibody
positive patients revealed dynamic changes in antibody
titers over time. In some cases, the induced autoanti-
body titers showed a marked increase of 50 to 100-fold
over the course of a few days (Figure 3). For example,
the anti-Ro52 autoantibodies in ARDS patient A31
increased from 1,000 LU at day 10 to over 1 million LU
by day 14 (Figure 3). A similar rapid rise in anti-ATPase
and anti-KCNRG autoantibodies was also seen in
patient A31 (Figure 3). Another patient (A5) showed a
rapid rise in anti-Ro52 and to lesser extent anti-GAD65
autoantibodies, between days 1 and 10 after ICU admis-
sion (Figure 3). For patient A23, there was a dramatic
rise in anti-IL-6 autoantibodies between day 0 and day 8
(Figure 3). A number of other patients including A14,
A22, A10, and A17 showed autoantibody titer increases
over time (Figure 3). Other patients, however, displayed
high antibody titers from the beginning of their ICU
admission, but showed an upward increase in antibody
titers that peaked at day 8 (see the IL-6 serial titers
inpatient A30; Figure 3). Lastly, some of these elevated
autoantibodies remained high at the last serum sample
collected at later time points such as at days 20 and 28
(Figure 3). Similar autoantibody titer increases and
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Page 5 of 9Figure 2 Heatmap analysis of autoantibody profiles in ARDS and sepsis patients. Autoantibody titers to the informative autoantigens are
shown for each of the 35 ARDS patient and 13 sepsis patients. The titer values greater than the mean of the 24 normal volunteers plus 3 SD
were color-coded from green to dark purple to signify the relative number of SD above these reference values. Shaded codes denote patients
who received corticosteroids as part of their treatment.
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patients (Figure 3). These results strongly suggest that
autoantibodies can be rapidly induced and can markedly
fluctuate during conditions of severe inflammation and/
or infection such as ARDS and sepsis.
Discussion
Our findings document the relatively high prevalence of
autoantibodies in acute, inflammatory, high mortality
conditions of ARDS and severe sepsis. The high detec-
tion rate of autoantibodies, 57% in ARDS and 46% in
severe sepsis patients using a relatively small panel of
autoantigens, suggests that the observed immunoreactiv-
ity to self proteins is a relatively common phenomenon
in these two conditions. The most frequent autoantigen
target in ARDS and sepsis was KCNRG, a protein highly
expressed in the lung [20]. While autoantibodies to
KCNRG have only been previously reported in a subset
of autoimmune polyendocrine syndrome patients with
lung complications [20], our finding of anti-KCNRG
autoantibodies in ARDS and sepsis patients is consistent
with the pulmonary injury and tissue destruction asso-
ciated with these conditions. The detection of autoanti-
bodies to the gastric ATPase autoantigen, a frequent
target in a number of autoimmune conditions including
autoimmune gastritis [21], type I diabetes [22] and Sjög-
ren’s syndrome [16], suggests that the stomach may be a
highly promiscuous target of autoantibody attack in
diverse inflammatory and autoimmune conditions. It
should also be noted that many of the patients were
concurrently on corticosteroids, but did not appear to
block autoantibody production. The finding of the rapid
induction of autoantibodies against the Ro52 autoanti-
gen, one of the major rheumatological antigens compris-
ing the SSA test, may coincide with the massive increase
in antibodies directed at potential pathogens and human
Figure 3 Rapid and dynamic changes in autoantibody titer in ARDS and Sepsis patients. Representative patient samples positive at day 10
for ARDS or day 14 for sepsis were reexamined for changes in antibody titers using all available serial samples. The antibody titers in LU plus
standard error bars are plotted on the Y-axis using a log10 scale. The X-axis represents time in days following admission to the ICU.
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studies suggest that Ro52 autoantigen plays an impor-
tant role in quality control of misfolded immunoglobu-
lins produced by B-lymphocytes [23] and may be
released from dying lymphocytes and other cells.
Consistent with the intense host inflammatory
response found in ARDS (5) and sepsis [3], high titer
autoantibodies were detected to a number of cytokines
including IL-6, interferon-ω, interferon-g and interleu-
kin-1-a. In contrast to a previous report [24], we were
unable to detect autoantibodies to IL-8 in any of the sam-
ples. Nevertheless, the finding that some patients show
autoantibodies to a number of cytokines suggests that
these antibodies may be biomarkers for the high levels of
cytokines which may cause autoimmunization and possi-
bly contribute to immune dysfunction seen in ARDS and
sepsis. Alternatively these autoantibodies may play a role
patient susceptibility to opportunistic infection. For
example, anti-INF-g autoantibodies are found in patients
with susceptibility to non-tuberculosis mycobacterium
infection [25-27], anti-IL-6 has been reported in a patient
with chronic skin infection [28], and a variety of anti-
cytokine autoantibodies are detected in a subset of thy-
moma patients with opportunistic infections [18,29,30].
Interestingly, 1 sepsis and 3 ARDS patients had relatively
high titer autoantibodies against IL-6 and/or INF-ω sug-
gesting that these autoantibodies might have a role in
dampening the activity of these cytokines. Future investi-
gations using other bioassays, such as looking for cyto-
kine neutralizing activity, are necessary to further
understand the functional significance of anti-cytokine
autoantibodies in ARDS and sepsis.
Many of the autoantibody responses detected in ARDS
and severe sepsis patients showed dynamic responses and
marked changes in titer over a short period of time.
Overall the findings of the rapid induction of autoantibo-
dies against one or several autoantigen targets in the
same patients do not support a role of molecular mimicry
in inducing these antibodies. The mechanism for the
rapid production of autoantibodies is intriguing. Long-
term memory B-cells which are responsible for the extra-
ordinary longevity of human serological memory [31]
may also be involved in the rapid synthesis of autoantibo-
dies described here. Rather than the long-term memory
B-cells directed against pathogen proteins, small numbers
of memory B-cells directed against self proteins may be
present in all humans, but in most cases remain dormant.
Following re-exposure to these self-antigens from tissue
destruction and/or other antigen-independent mechan-
ism including activation of cytokines and toll receptors,
these memory B-cells may expand and differentiate into
autoantibody producing plasma cells. Consistent with
this notion is the finding that many of the autoantibody
titers peaked at days 7-14 which may correlate with the
time frame needed to induce these autoantibodies after
the start of the inflammatory host response. Lastly, the
time course for the rapid induction of autoantibodies
seen in ARDS and sepsis may occur in other conditions
including autoimmune diseases.
Although this study focused on short-term outcomes, it
is intriguing that at these early time points autoantibodies
associated with neurological targets are detected. There is
evidence suggesting that ARDS patients suffer long-term
adverse neuromuscular sequelae [32], and it is possible
that autoantibodies and T-cell-mediated autoimmunity
might contribute to these problems at later time points.
For example, the presence of autoantibodies against AQP-
4 and GAD65 in some ARDS and sepsis patients may be
related to long-term neurological deficits seen in these
patients. Anti-AQP-4 autoantibodies are found in patients
with neurological complications including autoimmune
attack on the optic nerve, spinal cord and peripheral
nerves [16,33,34]. Anti-GAD65 autoantibodies have also
been reported in a number of different neurological dis-
eases including Stiff person syndrome, encephalitis and
epilepsy, as well as being the major autoantigen in type I
diabetes [35]. It is possible that the anti-AQP-4 and anti-
GAD65 autoantibodies reflect autoimmune attack on the
nervous system triggered by these conditions. Consistent
with this possibility, it is interesting to note that some of
autoantibodies detected in ARDS including to KCNRG,
AQP-4 and GAD65, show sustained elevation past the last
collected plasma samples at day 20 to 28. Since we were
unable to analyze long-term outcome of these patients, it
is unclear whether the presence of these autoantibodies
are associated with long-term sequelae of critical illness. It
is also unclear whether subsequent mild infections, inflam-
mation and other trauma might reactivate autoantibody
production at a later time in certain seropositive patients.
Future studies expanding the autoantigen panel, profiling
later time points and attempting to correlate autoantibody
elevation with relevant clinical outcomes are needed to
understand whether these autoantibodies have pathophy-
siological consequences.
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